Tracking Medicare news, policy, and coverage changes.
Eligible seniors will be able to use one or more of Lark’s 12 chronic disease management and prevention programs with no out-of-pocket costs through Samsung Health.
Read full article →Federal regulators approved a first-of-its-kind cholesterol medication from Merck that rivals the effectiveness of powerful drugs already on the market. The Food and Drug Administration (FDA) greenlit the once-daily pill called Lipfendra. Lipfendra reduces “bad,” or low-density lipoprotein cholesterol (LDL-C) in adults by inhibiting the production of PCSK9 proteins. Lipfendra is the first drug that...
Read full article →A ballot measure to eliminate Missouri’s income tax would give the state legislature broad authority to levy new sales taxes to replace the lost revenue. Critics say that could mean adding a sales tax on medical services or prescription medicines. Those types of taxes are unusual, but not unheard of, in the U.S.
Read full article →KFF Health News gives readers a chance to comment on a recent batch of stories.
Read full article →If we do not get this right, we may inadvertently cause a new sarcopenia epidemic while congratulating ourselves on solving obesity. The post GLP-1s Are Working — Now Medicine Needs to Measure What Matters appeared first on MedCity News .
Read full article →For years, the healthcare industry treated data collection as the main challenge. The next phase is about interpretation, coordination, and operational usability. The post Building AI-Ready Public Health Data Systems for Faster, Safer Decisions appeared first on MedCity News .
Read full article →Kalshi, one of the world’s largest prediction market exchanges, plans to take bets on clinical trials and regulatory approvals
Read full article →Kalshi allows bets on clinical trial outcomes, Eli Lilly buys a psychedelic medicine, and more biotech news from The Readout
Read full article →Prediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry could be next.
Read full article →Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
Read full article →Trump's pandemic preparedness nominee testifies, the "fang-to-pharmacy" pipeline, and more health news from Morning Rounds
Read full article →Amylyx Pharmaceuticals will soon read out results from a study evaluating a new treatment for a rare endocrine disorder, a pivotal moment for patients and the company.
Read full article →